Education
About Us
Working with TipRanks
Follow Us
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
2315 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.60 - HK$31.34
Previous CloseN/A
Volume49.50K
Average Volume (3M)521.33K
Market Cap
HK$10.67B
Enterprise ValueHK$9.10B
Total Cash (Recent Filing)HK$486.84M
Total Debt (Recent Filing)HK$614.18M
Price to Earnings (P/E)70.9
Beta1.09
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding110,781,920
10 Day Avg. Volume333,350
30 Day Avg. Volume521,329
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)3.81
Price to Sales (P/S)3.24
P/FCF Ratio18.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$27.00Price Target Upside5.63% Upside
Rating ConsensusHold
Number of Analyst Covering0
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News
2315 FAQ
What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$5.60 and its highest was HK$31.34 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$10.67B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 171 days.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Aug 28, 2025. The company reported HK$0.131 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.131.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
According to Wall Street analysts Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price is currently Undervalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of HK$0.131 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.697%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$27.00 (5.63% Upside)
HK$27.00 (5.63% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
233.68%
12-Months-Change
Fundamentals
Return on Equity
16.13%
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) is a biotechnology company specializing in the development of innovative antibody-based drugs. The company operates within the pharmaceutical and biotechnology sectors, focusing on research and development of therapeutic antibodies for a range of diseases, including cancer and autoimmune disorders. Biocytogen leverages its proprietary platforms to accelerate the discovery and development of novel therapeutics.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shandong Boan Biotechnology Company., Limited. Class H
―